Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Uterine Cervical Neoplasms 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Solid Tumor 1Rectal Neoplasms 1Oligometastatic Prostate Cancer 1Neoplasms 1Metastatic Urothelial Cancer 1Lung Neoplasms 1Lung Diseases 1Locally Advanced Cervical Cancer 1Gestational Trophoblastic Disease 1Gastro-enteropancreatic neuroendocrine tumor 1Erythrocytosis, Familial, 4 1Cholangiocarcinoma 1Carcinoid Tumor 1Breast Neoplasms 1Bile Duct Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

cabozantinib 7pembrolizumab 6Nivolumab 6Ipilimumab 5Axitinib 5Radiosurgery 3Blood Specimen Collection 3zimberelimab 2lenvatinib 2Ultrasonography 2Radiotherapy 2Biopsy 2tislelizumab 1polyethylene glycol 3350 1pazopanib 1palbociclib 1orellanine 1olaparib 1gallium Ga 68 dotatate 1fludarabine 1cyclopropapyrroloindole 1brodalumab 1belzutifan 1atezolizumab 1anlotinib 1adagrasib 1Watchful Waiting 1Vincristine 1Therapeutics 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Kidney Neoplasms × zimberelimab × Clear all
NCT05536141 2026-05-01

ARC-20

Arcus Biosciences, Inc.

Phase 1 Recruiting
362 enrolled
Genitourinary

Erythrocytosis, Familial, 4, Carcinoma, Renal Cell, Kidney Neoplasms

NCT07397611 2026-03-20

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Dana-Farber Cancer Institute

Phase 2 Recruiting
32 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡